Your AI-Trained Oncology Knowledge Connection!
The combination of atezolizumab and cabozantinib elicited encouraging responses, marked by an unprecedented disease control rate, in previously treated patients with locally advanced or metastatic castration-resistant prostate cancer, but most strikingly in patients with high-risk features.
Frontline immunotherapy resulted in improved progression-free survival and overall survival compared with sunitinib in patients with advanced renal cell carcinoma; however, determining the benefit in those with favorable-risk disease must be examined further.
Patients with clear cell renal cell carcinoma who received the combination of pembrolizumab and axitinib over sunitinib showed a benefit in adjusted overall survival and type and timing of subsequent therapy in a second interim analysis of the phase 3 KEYNOTE-426 study.
